OneVentures backs cancer biotech ImmVirX in $25 million Series B
Sydney VC OneVentures has pledged $15 million as a cornerstone investment towards a $25 million Series B raise for life sciences startup ImmVirX. The biotech startup is developing cancer treatments using oncolytic viral immunotherapies (viruses that infect and destroy cancer cells without damaging normal cells). The remaining $10 million in the Series offered to existing… Read more »
















